水飞蓟素治疗非酒精性脂肪性肝炎的随机试验
在马来西亚吉隆坡一家三级医院进行的随机双盲安慰剂对照试验中,99例经活检证实的非酒精性脂肪性肝炎(NASH)且NAFLD活动度评分(NAS)≥4的成人被分配接受水飞蓟素(700 mg,每日3次,n=49)或安慰剂(n=50)治疗48周。水飞蓟素组达到主要疗效终点(NAS降低≥30%)的比例为32.7%,安慰剂组为26.0%,两组无显著差异(P=.467)。水飞蓟素可能减轻肝纤维化,但需更大规模试验证实,且似乎安全且耐受良好。
要点
- 水飞蓟素700 mg每日3次治疗48周未显著提高NAS降低≥30%的患者比例(32.7% vs 26.0%,P=.467)。
- 水飞蓟素组组织学纤维化改善≥1分的比例为22.4%,显著高于安慰剂组的6.0%(P=.023)。
- 水飞蓟素组肝硬度下降≥30%的比例为24.2%,显著高于安慰剂组的2.3%(P=.002)。
核心结论
- 在99例NASH患者的随机试验中,水飞蓟素(700 mg,每日3次,治疗48周)并未使显著更大比例的患者NAS评分降低≥30%。
- 水飞蓟素可能减轻肝纤维化,但这仍需在更大规模的试验中证实。
- 水飞蓟素似乎安全且耐受良好。
研究设计与样本
- 随机、双盲、安慰剂对照试验,连续纳入经活检证实的NASH且NAFLD活动度评分(NAS)≥4的成人。
- 研究在马来西亚吉隆坡一家三级医院进行,时间为2012年11月至2014年8月。
- 患者随机分配至水飞蓟素组(700 mg,每日3次,n=49)或安慰剂组(n=50),治疗48周,之后重复肝活检。
- 主要疗效终点为NAS降低≥30%,比较48周肝活检与基线活检结果。
主要发现
- 达到主要疗效终点的患者比例两组无显著差异:水飞蓟素组32.7% vs 安慰剂组26.0%(P=.467)。
- 基于组织学纤维化改善≥1分的患者比例,水飞蓟素组为22.4%,显著高于安慰剂组的6.0%(P=.023)。
- 基于肝硬度测量下降≥30%的患者比例,水飞蓟素组为24.2%,显著高于安慰剂组的2.3%(P=.002)。
- 水飞蓟素组天冬氨酸氨基转移酶与血小板比值指数平均降低0.14(与基线比较P=.011),纤维化-4评分平均降低0.20(P=.041),NAFLD纤维化评分平均降低0.30(P<.001);安慰剂组相应变化分别为降低0.07(P=.154)、升高0.18(P=.389)和降低0.05(P=.845)。
- 两组不良事件数量无显著差异;发生的不良事件未归因于水飞蓟素。
局限性
- 水飞蓟素可能减轻肝纤维化,但这仍需在更大规模的试验中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Silymarin is a complex mixture of 6 major flavonolignans and other minor polyphenolic compounds derived from the milk thistle plant Silybum marianum; it has shown antioxidant, anti-inflammatory and antifibrotic effects, and may be useful in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to study the efficacy of silymarin in patients with nonalcoholic steatohepatitis (NASH)-the more severe form of NAFLD. METHODS: We performed a randomized, double-blind, placebo-controlled trial of consecutive adults with biopsy-proven NASH and a NAFLD activity score (NAS) of 4 or more at a tertiary care hospital in Kuala Lumpur, Malaysia, from November 2012 through August 2014. Patients were randomly assigned to groups given silymarin (700 mg; n = 49 patients) or placebo (n = 50 patients) 3 times daily for 48 weeks. After this 48-week period, liver biopsies were repeated. The primary efficacy outcome was a decrease of 30% or more in NAS; findings from 48-week liver biopsies were compared with those from the baseline biopsy. Secondary outcomes included changes in steatosis, lobular inflammation, hepatocyte ballooning, NAS and fibrosis score, and anthropometric measurements, as well as glycemic, lipid, and liver profiles and liver stiffness measurements. RESULTS: The percentage of patients achieving the primary efficacy outcome did not differ significantly between the groups (32.7% in the silymarin group vs 26.0% in the placebo group; P = .467). A significantly higher proportion of patients in the silymarin group had reductions in fibrosis based on histology (reductions of 1 point or more; 22.4%) than did the placebo group (6.0%; P = .023), and based on liver stiffness measurements (decrease of 30% or more; 24.2%) than did the placebo group (2.3%; P = .002). The silymarin group also had significant reductions in mean aspartate aminotransferase to platelet ratio index (reduction of 0.14, P = .011 compared with baseline), fibrosis-4 score (reduction of 0.20, P = .041 compared with baseline), and NAFLD fibrosis score (reduction of 0.30, P < .001 compared with baseline); these changes were not observed in the placebo group (reduction of 0.07, P = .154; increase of 0.18, P = .389; and reduction of 0.05, P = .845, respectively). There was no significant difference between groups in number of adverse events; adverse events that occurred were not attributed to silymarin. CONCLUSIONS: In a randomized trial of 99 patients, we found that silymarin (700 mg, given 3 times daily for 48 weeks) did not reduce NAS scores by 30% or more in a significantly larger proportion of patients with NASH than placebo. Silymarin may reduce liver fibrosis but this remains to be confirmed in a larger trial. It appears to be safe and well tolerated. ClinicalTrials.gov: NCT02006498.
引用
- Wah Kheong C, Nik Mustapha NR, Mahadeva S, et al. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017. PMID: 28419855. doi:10.1016/j.cgh.2017.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。